Depression, Anxiety, and Patterns of Mental Health Care Among Men With Prostate Cancer Receiving Androgen Deprivation Therapy

• Published in: The oncologist (Dayton, Ohio) Ohio), 2022-04, Vol.27 (4), p.314-322
• Main Authors: Tsao, Phoebe A, Ross, Ryan D, Bohnert, Amy S B, Mukherjee, Bhramar, Caram, Megan E V
• Format: Article
• Language: English
• Subjects: Androgen Antagonists - adverse effects; Androgens; Androgens - therapeutic use; Antiandrogens; Anxiety - epidemiology; Anxiety - etiology; Benzodiazepines; Depression - epidemiology; Depression - etiology; Development and progression; Evidence-based medicine; Genitourinary Cancer; Health care reform; Humans; Male; Mental Health; Prostate cancer; Prostatic Neoplasms - epidemiology; Psychiatric services; Psychological aspects; Psychotropic drugs
• ISSN: 1083-7159; 1549-490X
• DOI: 10.1093/oncolo/oyab033

Androgen deprivation therapy (ADT) use is associated with an increased risk of developing depression and anxiety. Little is known about how the mental health of these men is treated. We identified men with prostate cancer who received ADT between 2001 and 2015 using Optum's de-identified Clinformatics Data Mart Database. We determined the incidence of depression or anxiety diagnoses, mental health treatments, and the specialty of providers initiating psychotropic medications, after the start of ADT. Outcomes were compared with those of men with prostate cancer not receiving ADT and men without prostate cancer. Of 37 388 men with prostate cancer treated with ADT, 3964 (10.6%) received a new diagnosis of depression or anxiety. Of those 3964 men, 1892 (47.7%) did not receive a documented treatment, 10 (0.3%) received psychotherapy, 1321 (33.3%) a selective serotonin reuptake inhibitor, and 744 (18.8%) a benzodiazepine. The median time from initiation of ADT to a depression or anxiety diagnosis was 9.3 months. Primary care physicians were the most common prescribers of psychotropic medications (72.2%). The proportion of men not receiving mental health treatments of interest (47.7%) was similar compared to men without prostate cancer (49.1%), but statistically significantly lower compared to men with prostate cancer not receiving ADT (52.7%). In men with prostate cancer receiving ADT with a new diagnosis of depression or anxiety, nearly half are not receiving mental health care while one in five is introduced to a benzodiazepine. Further investigation toward improving the mental health care for men on ADT is needed.